Tim-Jonathan Koppe (Leipzig), Theresa Wald (Leipzig), Veit Zebralla (Leipzig), Andreas Dietz (Leipzig), Susanne Wiegand (Leipzig), Markus Pirlich (Leipzig), Matthäus Stöhr (Leipzig), Gunnar Wichmann (Leipzig)
Introduction
Early laryngeal cancer and especially glottic carcinomas can be safely cured by resection and achieve the best survival rates amongst head and neck cancer. As accurate distinction between of glottic (GC) or supraglottic carcinoma (SGC) is hampered by anatomical proximity of glottis and supraglottic region, we asked if overall survival (OS) varies.
Methods
Patients diagnosed 2007-2020 with stage I or II GC or SGC (ICD-10C32.0, C32.1, C32.8 or C32.9) were included as part of a monocentric, retrospective study at the Leipzig University Hospital. Before survival analyses, we closely examined reports about biopsy excision and definitive surgery to differentiate more precisely between GC and SGC.
Results
225 patients with early GC and SGC were included. After tumor-resection, 5 patients were reclassified into higher UICC stage; 18 had carcinoma in situ. While OS in the 131 UICC stage I patients did not differ between localizations, n=46 UICC stage II GC patients had superior mean OS (109.8, 95% confidence interval (CI) 86.3-133.4 months; median OS 107.7, 95% CI 88.7-126.7 months) compared to n=25 SGC (mean 75.2, 95% CI 53.0-97.4 months; median 77.3, 95% CI 32.6-122.0 months; p=.085). Altogether, OS was superior for GC (mean 123.8, 95% CI 112.3-135.3 months, median 147.1, 95% CI 107.7-186.5 months) vs. SGC (mean 79.9, 95% CI 60.2-99.6 months, median 77.3, 95% CI 44.8-109.8 months; p<.001).
Discussion
OS in patients with GC or SGC differs significantly. Consequently, great effort increase accuracy in differentiating between both types of laryngeal cancer will improve prognostication. SGC patients will benefit from closer surveillance and potentially from modified therapy regimens.
Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.